anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The invention relates to a binuclear zinc complex and a preparation method and applications thereof. The chemical formula of the binuclear zinc complex is [Zn2L(OAc)2(CH3OH)4](ClO4)2, wherein L is 4,4'-bis(N,N-bis(pyridine-2-methyl)) diaminodiphenyl methane, and OAC is acetate radical. The compound crystal belongs to a monoclinic system, the space group is C2/c, and the crystal cell parameter beta is 117.93(3) degrees. The target compound is prepared by reaction between the ligand L.xHClO4 and zinc acetate. A plurality of spectrographic methods represent and discover that the compound has stronger bonding effect on the CT-DNA; agarose electrophoresis experiment verifies that the compound has obvious cutting effect on Pbr322 DNA; and the MTT experiment verifies that the compound has better anti-cancer activity to HeLa cells, so that the binuclear zinc complex can be used as potential anti-cancer drugs. The preparation method is simple and reliable.
The invention concerns water-containing skin-cleansing agents in liquid, paste or cream form designed to remove strongly adhering dirt, the agents containing anionic and/or amphoteric and/or non-ionic surfactants as wash-active substances, thickeners, at least one abrasive plus, optionally, auxiliaries for regulating the appearance consistency, odour and stability such as pigments, fragrances, stabilizers and preservatives. The agents are characterized in that the only solvent they contain is di-n-butyl and/or diisopropyl adipate. The agents are prepared by thorough mixing of the ingredients, the mixture optionally being heated. If a C8-C16 fatty alcohol is added as a consistency regulator, heating of the mixture becomes unnecessary. Furthermore, the addition of a fatty alcohol enhances the cleansing action. The invention also concerns the use of such skin-cleansing agents, the agent first being spread on to the skin without the addition of water or with the addition of a small quantity of water, and the cleansing process continued and completed by rinsing with water.
Tumors were observed in the urinary bladder of male rats in the two-year carcinogenicity study [see Nonclinical Toxicology (13.1)]. In two 3-year trials in which ACTOS was compared to placebo or glyburide, there were 16/3656 (0.44%) reports of bladder cancer in patients taking ACTOS compared to 5/3679 (0.14%) in patients not taking ACTOS. After excluding patients in whom exposure to study drug was less than one year at the time of diagnosis of bladder cancer, there were six (0.16%) cases on ACTOS and two (0.05%) cases on placebo.

A five-year interim report of an ongoing 10-year observational cohort study found a non-significant increase in the risk for bladder cancer in subjects ever exposed to ACTOS, compared to subjects never exposed to ACTOS (HR 1.2 [95% CI 0.9 – 1.5]). Compared to never exposure, a duration of ACTOS therapy longer than 12 months was associated with an increase in risk (HR 1.4 [95% CI 0.9 – 2.1]), which reached statistical significance after more than 24 months of ACTOS use (HR 1.4 [95% CI 1.03 – 2.0]). Interim results from this study suggested that taking ACTOS longer than 12 months increased the relative risk of developing bladder cancer in any given year by 40% which equates to an absolute increase of 3 cases in 10,000 (from approximately 7 in 10,000 [without ACTOS] to approximately 10 in 10,000 [with ACTOS]).

There are insufficient data to determine whether pioglitazone is a tumor promoter for urinary bladder tumors. Consequently, ACTOS should not be used in patients with active bladder cancer and the benefits of glycemic control versus unknown risks for cancer recurrence with ACTOS should be considered in patients with a prior history of bladder cancer.
BACKGROUND: Procollagen type III N-terminal peptide (P-III-NP) is a fibrosis biomarker associated with liver and cardiac fibrosis. Despite the value of P-III-NP as a biomarker, its analysis currently relies on enzyme-linked immunosorbent assays (ELISA) and radioimmunoassays (RIA), which require more than 3 h. To facilitate early diagnosis and treatment through rapid biomarker testing, we developed a one-step immunoassay for P-III-NP using a quenchbody, which is a fluorescence-labeled immunosensor for immediate signal generation.
RESULTS: To create quenchbodies, the total mRNA of P-III-NP antibodies was extracted from early-developed hybridoma cells, and genes of variable regions were obtained through cDNA synthesis, inverse PCR, and sequencing. A single-chain variable fragment (scFv) with an N-terminal Cys-tag was expressed in E. coli Shuffle T7, resulting in a final yield of 9.8 mg L-1. The fluorescent dye was labeled on the Cys-tag of the anti-P-III-NP scFv using maleimide-thiol click chemistry, and the spacer arm lengths between the maleimide-fluorescent dyes were compared. Consequently, a TAMRA-C6-labeled quenchbody exhibited antigen-dependent fluorescence signals and demonstrated its ability to detect P-III-NP at concentrations as low as 0.46 ng mL-1 for buffer samples, 1.0 ng mL-1 for 2 % human serum samples.
SIGNIFICANCE: This one-step P-III-NP detection method provides both qualitative and quantitative outcomes within a concise 5-min timeframe. Furthermore, its application can be expanded using a 96-well platform and human serum, making it a high-throughput and sensitive method for testing fibrotic biomarkers.
PCT No. PCT/FR94/00301 Sec. 371 Date Oct. 25, 1995 Sec. 102(e) Date Oct. 25, 1995 PCT Filed Mar. 18, 1994 PCT Pub. No. WO94/21764 PCT Pub. Date Sep. 29, 1994A process for preparation of a fat fraction of vegetable origin enriched with unsaponifiable materials. A fat of vegetable origin is treated with a hot polar solvent of the ketone type to obtain a first fraction insoluble in the hot ketone solvent which is rich in unsaponifiable materials, and a second fraction which is a solution of hot soluble materials. The first fraction is then separated from the second fraction, and the second fraction is subjected to a crystallization in a crystallization solvent at a temperature below 0 DEG  C., followed by filtering to obtain a filtrate. The crystallization solvent is then evaporated from the filtrate to obtain a further fraction rich and unsaponifiable materials.
Sulfasalazine is split by bacterial action in the colon into sulfapyridine (SP) and mesalamine (5-ASA). It is thought that the mesalamine component is therapeutically active in ulcerative colitis. The usual oral dose of sulfasalazine for active ulcerative colitis in adults is 2 to 4 g per day in divided doses. Four grams of sulfasalazine provide 1.6 g of free mesalamine to the colon.

The mechanism of action of mesalamine (and sulfasalazine) is unknown, but appears to be topical rather than systemic. Mucosal production of arachidonic acid (AA) metabolites, both through the cyclooxygenase pathways, ie, prostanoids, and through the lipoxygenase pathways, ie, leukotrienes (LTs) and hydroxyeicosatetraenoic acids (HETEs), is increased in patients with chronic inflammatory bowel disease, and it is possible that mesalamine diminishes inflammation by blocking cyclooxygenase and inhibiting prostaglandin (PG) production in the colon.

Human Pharmacokinetics and Metabolism  
Absorption. PENTASA is an ethylcellulose-coated, controlled-release formulation of mesalamine designed to release therapeutic quantities of mesalamine throughout the gastrointestinal tract. Based on urinary excretion data, 20% to 30% of the mesalamine in PENTASA is absorbed. In contrast, when mesalamine is administered orally as an unformulated 1-g aqueous suspension, mesalamine is approximately 80% absorbed.

Plasma mesalamine concentration peaked at approximately 1 μg/mL 3 hours following a 1-g PENTASA dose and declined in a biphasic manner. The literature describes a mean terminal half-life of 42 minutes for mesalamine following intravenous administration. Because of the continuous release and absorption of mesalamine from PENTASA throughout the gastrointestinal tract, the true elimination half-life cannot be determined after oral administration. N-acetylmesalamine, the major metabolite of mesalamine, peaked at approximately 3 hours at 1.8 μg/mL, and its concentration followed a biphasic decline. Pharmacological activities of N-acetylmesalamine are unknown, and other metabolites have not been identified. 

Oral mesalamine pharmacokinetics were nonlinear when PENTASA capsules were dosed from 250 mg to 1 g four times daily, with steady-state mesalamine plasma concentrations increasing about nine times, from 0.14 μg/mL to 1.21 μg/mL, suggesting saturable first-pass metabolism. N-acetylmesalamine pharmacokinetics were linear.

Elimination. About 130 mg free mesalamine was recovered in the feces following a single 1-g PENTASA dose, which was comparable to the 140 mg of mesalamine recovered from the molar equivalent sulfasalazine tablet dose of 2.5 g. Elimination of free mesalamine and salicylates in feces increased proportionately with PENTASA dose. N-acetylmesalamine was the primary compound excreted in the urine (19% to 30%) following PENTASA dosing.
Calcium phosphate cement which can be used as biomaterial. A calcium phosphate cement has been invented which can be used as biomaterial. The essential active ingredient is Ca2NaK(PO4)2. A second active ingredient can be both phosphoric acid and a primary salt of a phosphate of Na+, K+, Mg2+, Ca2+ and/or Zn2+. In order to improve its properties, other ingredients are added such as non- reactive carbonates, sulphates and/or phosphates of Na+, K+, Mg2+, Ca2+ and/or Zn2+. A special characteristic of this cement in dental applications is that it promotes the sealing of the dentinal tubules when precipitation of the calcium phosphates inside them is induced.
FIELD: medicine, pharmacy. SUBSTANCE: invention proposes pharmaceutical composition and method suppressing appetite. Composition comprises peptide of the formula (I) given in description that inhibits appetite. Invention allows to effect on inhibition of food consumption with the enhanced efficiency by peripheral route of administration. EFFECT: enhanced effectiveness of composition, valuable medicinal property. 17 cl, 2 dwg, 9 ex
<P>PROBLEM TO BE SOLVED: To provide a composition efficiently exhibiting various kinds of physiological activities latently possessed by seaweed of the genus Porphyra.  <P>SOLUTION: The Porphyra sp. protein-containing composition is obtained by adding water, a saline solution or a dilute aqueous solution of an alkali to a thallus or a dried finely granulated material of the seaweed of the genus Porphyra, extracting a soluble ingredient while carrying out wet grinding and conducting a separation treatment of the protein from the extract liquid. The extraction with the saline solution or the dilute aqueous solution of the alkali may separately be performed to provide each of separate Porphyra sp. protein-containing compositions or the operations may successively be carried out to mix each of the compositions.Thereby, the Porphyra sp. protein-containing composition is obtained. The resultant Porphyra sp. protein-containing composition has the physiological activities such as hypotensive actions, hepatic function improving actions, lipid metabolism improving actions, peripheral vasodilator actions and blood viscosity-lowering actions. Thereby, the composition is used as a food effective for health.  <P>COPYRIGHT: (C)2004,JPO
A new analytical method for chronic kidney disease (CKD) detection utilizing paper spray mass spectrometry (PS-MS) combined with machine learning is presented. The analytical protocol is rapid and simple, based on metabolic profile alterations in urine. Anonymized raw urine samples were deposited (10 μL each) onto pointed PS-MS sample strips. Without waiting for the sample to dry, 75 μL of acetonitrile and high voltage were applied to the strips, using high resolution mass spectrometry measurement (15 s per sample) with polarity switching to detect a wide range of metabolites. Random forest machine learning was used to classify the resulting data. The diagnostic performance for the potential diagnosis of CKD was evaluated for accuracy, sensitivity, and specificity, achieving results >96% for the training data and >91% for validation and test data sets. Metabolites selected by the classification model as up- or down-regulated in healthy or CKD samples were tentatively identified and in agreement with previously reported literature. The potential utilization of this approach to discriminate albuminuria categories (normo, micro, and macroalbuminuria) was also demonstrated. This study indicates that PS-MS combined with machine learning has the potential to be used as a rapid and simple diagnostic tool for CKD.
The children in the VR groups were told to watch the video by wearing virtual glasses during the blood draw. By wearing the VR headsets in the VR-Ocean Rift Group, individuals can take an underwater tour with 12 different marine animals with slow music.
Oral pouch 1g, single dose. One pouch administered over 30 minutes. Buccal Administration of nicotine.
Individuals in the lowest SRI tertile will begin the 12-week intervention to improve sleep regularity. Participants will be instructed to maintain a consistent sleep onset time (±30 min self-selected sleep time).
The study will have a double-blind design and will be conducted after obtaining an approval from the local ethics committee. The study will include 50 patients planned for thoracotomy, aged 18-65 years with an ASA score of I-II. The patients will be randomized by sealed tender and will be divided into 2 groups with 25 patients each. Patients that will be transferred to the intensive care unit (ICU) intubated after the surgery, patients with a body mass index of 35 or over, patients detected with infection in the intervention site, patients with hematological diseases, patients with a known allergy to local anesthetics, patients that will not provide a written or verbal consent, pregnant patients, and patients with an ASA score of III or IV will be excluded from the study. All the patients will undergo physical examination and their laboratory parameters will be evaluated one day prior to the procedure. Moreover, on the same day, each patient will be informed about dermatome testing (hot/cold), pain prick test (pain test), and pain pump set. Age, body height and weight, duration of block, and duration of surgery will be recorded for each patient
Telephone Individualized Comprehensive Self-Management (CSM-TEL) Group. Participants in the individualized CSM-FTF group will initially have 2 face-to-face meetings with the nurse therapist, 6 sessions over the phone and the final session face-to-face at 9 weeks.
Pulmonary arterial hypertension (PAH) leads to premature death as a consequence of increased pulmonary vascular resistance and right heart failure. PAH-targeted therapies developed over the past 20 years target excessive vasoconstriction. However, the pathobiology of PAH is more complicated, and includes dysregulated vascular cell proliferation, cellular metabolic abnormalities, and inflammation. Even with modern PAH therapies, current outcomes remain poor, with an estimated 3-year survival rate of only 55%. Thus, there is a clear need for more effective therapies, based on better understanding of the pathobiology of the disease.

Insulin resistance has emerged as a potential new mechanism in PAH. Animal models of insulin resistance are associated with PAH, which reverses with the administration of insulin sensitizing drugs. Over the past decade there has been an epidemiologic shift in PAH, where the disease is increasingly observed in older, obese, and diabetic subjects. Low levels of high-density lipoprotein cholesterol in PAH, a feature of insulin resistance, have been observed and found to be a strong independent predictor of PAH mortality. Elevated glycosylated hemoglobin (HbA1c) also correlates with PAH diagnosis and severity. As measured by the OGTT, idiopathic PAH patients have not only insulin resistance, but also an inability to mount an appropriate insulin response to a glucose challenge. These data point to dysfunction in the pancreatic beta cells of PAH patients. It is known that an exercise and low glycemic index diet intervention improves insulin sensitivity in pre-diabetic subjects.
A lidar system comprises a lidar receiver that includes a first lens and a second lens. The first lens has a first field of view (FOV). The second lens has a second FOV, wherein the second FOV is encompassed by and narrower than the first FOV. A switch can control which of the first and second lenses are used for detecting returns from laser pulse shots based on where the laser pulse shots are targeted in a FOV that encompasses the first and second FOVs. The lidar receiver can include multiple readout channels for reading out signals from a photodetector array that senses light passed by the first and/or second lenses. Furthermore, the first and/or second lenses can be adjustable so that their respective FOVs are adjustable. Furthermore, shot scheduling for the lidar system can take into consideration potential changes in tilt amplitude of a variable amplitude scan mirror.
Participants with solid tumors or non-Hodgkin lymphoma (NHL) will receive JNJ-64619178 orally as per the assigned sequential cohorts and doses will be escalated based on the review of all available data including, but not limited to, pharmacokinetic, pharmacodynamic, safety, and clinical activity. One or more recommended Phase 2 dose(s) (RP2Ds) may be determined for further exploration.
PCT No. PCT/US95/03744 Sec. 371 Date Jun. 28, 1995 Sec. 102(e) Date Jun. 28, 1995 PCT Filed Mar. 28, 1995 PCT Pub. No. WO95/26138 PCT Pub. Date Oct. 5, 1995A composition of matter containing zinc gluconate gel as an irritant-inactivating agent, and a substance which substantially prevents the irritant-inactivating agent from binding to the surface, wherein the irritant-inactivating agent in the composition is present in an amount effective to inactivate irritants in fluids which contact the composition, is described. Surgical instruments and physical barriers with the aforementioned composition applied thereto are also described. A method of inactivating irritants in a fluid contacting skin comprising applying the aforementioned composition to the skin is also disclosed. A method of inactivating irritants in a fluid contacting skin covered with a physical barrier comprising applying the aforementioned composition to the skin is also disclosed.
Ultraviolet (UV) exposure triggers skin aging primarily by disrupting skin barrier function, resulting in dry skin and wrinkle formation. Oyster hydrolysate (OH), as a functional food, has been reported for anti-cancer, anti-oxidant and anti-apoptotic effects. This study investigated the underlying mechanism of OH effect on UVB-induced skin aging in SKH1 hairless mice. Mice were exposed to UVB three times per week while they were fed with a normal diet or diet containing OH for 10 weeks. Additionally, a randomized, double-blind, and placebo-controlled clinical trial was performed to investigate the OH effect on human skin moisturizing to evaluate its efficacy and safety. UVB exposure increased parameters of skin aging; dehydration, transepidermal water loss, and macroscopic dorsal skin lesions. OH significantly reduced these features of skin aging. Histological analysis demonstrated that OH decreased skin epidermal and dermal thickness and collagen degradation induced by UVB. OH significantly reduced ROS production, suppressed macrophage activation and neutrophil infiltration, and downregulated pro-inflammatory cytokine production. OH improved skin barrier function by increasing the expression of filaggrin, aquaporin-3, and hyaluronic acid synthesis enzymes and promoting recovery from skin damage. Importantly, the results from a human clinical trial demonstrated that OH improved skin moisturization and integrity with no side effects. Taken together, OH supplementation ameliorates skin damage via anti-oxidant and anti-inflammatory properties and enhances skin hydration and barrier function. OH has a therapeutic potential for skin photoaging.
The present invention relates to an iodine microsphere clathrate compound used for treating diseases of chronic pharyngolaryngitis, oral mucosa canker, chronic gingivitis, periodontitis, acute and chronic pharyngitis, tonsillitis, iodine deficiency diseases, etc. and a preparation method and uses thereof. The iodine microsphere clathrate compound comprises the components with a molecular molar ratio: 1 portion of iodine, 1 to 10 portions of iodine ions and 100 portions of hydroxypropyl-beta-cyclodextrin. The technology of cyclodextrin inclusion is applied, and a solvent method and a grinding method are adopted by the present invention so that a complex compound formed from the iodine and the iodine ions forms a microcapsule-shaped inclusion compound with molecules of the hydroxypropyl-beta-cyclodextrin. The inclusion compound can be used for preparing various iodine containing products. Compared with other iodine containing products, the present invention has the advantages of enhancement of iodine dissolvability, reduction of iodine mucosa irritation, mask of unfavorable abnormal smell of iodine and shortened sterilization time of iodine.
Ten cases of small intestinal tympany with or without volvulus were documented in Central American river turtles (Dermatemys mawii). These turtles were under managed care at the Philadelphia Zoo in Philadelphia, PA, USA, with one case followed after transfer to a different institution. The primary clinical presentation was abnormal buoyancy in nearly all cases (9/10) and anorexia in two cases (2/10). Five of 10 turtles with suspected or radiographically confirmed small intestinal tympany recovered (5/10), whereas five cases (5/ 10) resulted in death or euthanasia. In all fatal cases (5/5), small intestinal volvulus was identified at gross necropsy, with concurrent colonic volvulus identified in 2/5 cases. Other notable necropsy findings were hepatic lipidosis (3/5) and thrombosis of intestinal or renal vasculature (2/5). In all fatal cases (5/5), there was short (1 to 2 days) clinical progression from abnormal buoyancy to death or euthanasia. In the majority of cases (6/10), an abrupt change in diet, notably the overfeeding of fresh fruit or excessive amounts of mulberry (Morus spp.) browse, or ingestion of indigestible foreign material, occurred prior to presentation. Temporary suboptimal environmental temperatures were suspected prior to the onset of clinical signs in 4/10 cases. Optimal husbandry conditions including nutrition and environmental temperature appear vital to preventing this condition. Recognition of early clinical signs of this condition, such as abnormal buoyancy and anorexia, and environmental correction or medical therapy, may prevent fatality and result in a better outcome in these cases.
Patients who meet the protocol and sign the informed consent form received 4 cycles of chemotherapy combined with camrelizumab, followed by maintenance with camrelizumab until one year or the disease progressed or unacceptable toxicity. The chemotherapy regimen is decided by the researcher.
Participants will receive an indigestible fiber supplementation (classified) for a period of 8 weeks. Thrice daily, they will take the fiber powder during their meals.
Participants receive montelukast 5 mg chewable tablets for 7 days during Period 1 and receive placebo chewable tablets for 7 days during Period 2. There is a 7-day washout period between Periods 1 and 2.